Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT03518268 Not yet recruiting - Breast Cancer Clinical Trials

Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor

Start date: May 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention of bone loss occurring in post menopausal women with breast cancer treated with an aromatase inhibitor. Half of the participants will receive Vivomixx while the other half will receive a placebo. The primary endpoint is to assess changes of bone turnover markers during the period of 6 months.

NCT ID: NCT03513107 Recruiting - Osteoporosis Clinical Trials

Osteoporosis Screening Tools' Re-validation in Egypt Guide for the Management of the Condition in Males

Start date: January 15, 2018
Phase:
Study type: Observational [Patient Registry]

To demonstrate the predictive ability of the different screening scores (i.e. OST, ORAI, ABONE, body weight criterion, age alone or others) and their potential use in the primary care setting.

NCT ID: NCT03512743 Enrolling by invitation - Clinical trials for Postmenopausal Osteoporosis

Association of Serum Ferritin and Bone Mineral Density With Bone Metabolism in Chinese Healthy Postmenopausal Women

Start date: May 1, 2018
Phase:
Study type: Observational

Large amounts of experimental and animal evidence have confirmed that iron accumulation is associated with bone loss. However, it is still lack of the clinical studies relating iron accumulation to bone loss, especially in the pathological conditions during our Chinese. In this study, the investigators aim to assess the association between the levels of serum ferritin and bone mineral density in Chinese healthy postmenopausal women.

NCT ID: NCT03512262 Recruiting - Osteoporosis Clinical Trials

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Start date: March 30, 2018
Phase: Phase 3
Study type: Interventional

A 12 month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.

NCT ID: NCT03503552 Completed - Osteoporosis Clinical Trials

Body Composition and Risk for Development of Pre-diabetes in Post-menopausal Chinese Women in Singapore

Start date: February 13, 2015
Phase:
Study type: Observational

This project aims to ascertain that novel imaging and metabolic markers can be used to identify as well as to validate and improve the detection of Singapore-Chinese women at increased risk of diabetes.

NCT ID: NCT03484208 Recruiting - Clinical trials for Osteoporotic Fractures

Evaluation of a Fracture Liaison Service in the Osteoporosis Care

Start date: February 8, 2018
Phase:
Study type: Observational

The St JOSEPH'S HOSPITAL set up a fracture liaison service for osteopotic fracture. A specific nurse screens eligible patient admitted in emergency yard and call them to propose a bone densitometry and a medical coverage.. The aim of the study is to evaluate this new organisation

NCT ID: NCT03483584 Not yet recruiting - HIV Clinical Trials

Incidence of HANA Conditions in HIV-infected Individuals

Start date: April 6, 2018
Phase:
Study type: Observational

With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy. But at the same time, HIV-associated non-AIDS (HANA) conditions are becoming more important in their clinical management. It is currently uncertain whether patients started on different anti-retroviral regimens will have different incidence of HANA conditions. This study aims to evaluate the incidence of various HANA conditions in a cohort of newly diagnosed HIV-infected individuals in Hong Kong initiating anti-retroviral treatment. The incidence of various HANA conditions will be evaluated for those receiving INSTI versus other non-INSTI-based regimens. The HANA conditions evaluated will include 1. Hypertension 2. Diabetes and insulin resistance 3. Dyslipidemia 4. Lipodystrophy 5. Metabolic syndrome 6. Osteopenia and osteoporosis 7. Vitamin D deficiency 8. Renal impairment and kidney tubular dysfunction and 9. Liver fibrosis. Patients will be assessed prior to initiation of anti-retroviral therapy, and 48 weeks and 96 weeks after initiation of treatment. The incidence of development of each HANA condition will be determined and compared between those initiated different anti-retroviral regimens.

NCT ID: NCT03475719 Enrolling by invitation - Clinical trials for Osteoporosis, Postmenopausal

A Clinical Trial to Evaluate the Safety and Pharmacokinetic

Start date: January 11, 2018
Phase: Phase 1
Study type: Interventional

A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers

NCT ID: NCT03472846 Recruiting - Clinical trials for Postmenopausal Osteoporosis

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

Start date: March 1, 2017
Phase: Phase 4
Study type: Interventional

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

NCT ID: NCT03469518 Active, not recruiting - Osteoporosis Clinical Trials

Effect of β-cryptoxanthin (β-Cx), Plant Sterols and Galactooligosaccharides on Systemic and Gastrointestinal Markers

Start date: January 2017
Phase: N/A
Study type: Interventional

Regular consumption of a beverage containing β-cryptoxanthin (β-Cx) and plant sterols (PS) has been shown to exert a synergic effect in reducing some markers of cardiovascular risk and bone-remodeling (formation and resorption). The present project aims to: - Evaluate (by in vivo and in vitro studies) the bioavailability of added β-Cx, PS and galactooligosaccharides (GOS) and its stability in the beverage employed in the proposed study. - Study the biological effect (bioefficacy) associated with the regular consumption of modified milk-based fruit beverages containing β-Cx, PS and GOS in post-menopausal women (target group) by assessing changes in inflammation, cardiovascular and bone turnover biochemical markers. - Characterize genetic variability (polymorphisms), genetic expression and DNA oxidative damage in the target group as determinants of bioavailability and biological effects of β-Cx, PS and GOS. - Evaluate the potential prebiotic effect associated to regular consumption of a beverage supplemented with β-Cx, PS and GOS: including "in vitro" studies and characterization of subjects' microbiota and possible microbiota changes associated to the beverage consumption.